Therapy Name | Fulvestrant + Seribantumab |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 15 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells (NCI Drug Dictionary). Faslodex (fulvestrant) is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Seribantumab | MM-121|SAR256212 | HER3 (ERBB3) Antibody 13 | Seribantumab (SAR256212) is a human monoclonal antibody that binds ERBB3 (HER3) and prevents ligand binding and heterodimerization with other ERBB family members, resulting in decreased activation of downstream signaling and potentially leading to reduced tumor growth (PMID: 26310543). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03241810 | Phase II | Fulvestrant Fulvestrant + Seribantumab | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) | Recruiting |